Heron Therapeutics Reports Q1 2026 Financial Results in Earnings Call
Heron Therapeutics, Inc. (HRTX) held its first quarter 2026 earnings conference call on May 11, 2026, to discuss the company's recent financial performance and operational updates. The call featured key executives, including CEO Craig Collard, CFO Ira Duarte, COO Mark Hensley, and Chief Development Officer William Forbes. They addressed analysts from H.C. Wainwright & Co. and Needham & Company regarding the company's strategic direction and development pipeline. Melissa Jarel, Executive Director of Legal, opened the session with standard disclosures concerning forward-looking statements, cautioning investors that projections and expectations involve risks and uncertainties. The transcript provides insights into Heron Therapeutics' current business status, highlighting management's engagement with the investment community. As a biopharmaceutical company, Heron's updates are critical for stakeholders monitoring its progress in developing acute care therapies. The event serves as a formal platform for the company to communicate its quarterly results, answer investor questions, and outline future plans for the remainder of 2026, reflecting standard corporate transparency practices in the healthcare sector.
Wire timeline
Heron Therapeutics Reports Q1 2026 Financial Results in Earnings Call
Heron Therapeutics, Inc. (HRTX) held its first quarter 2026 earnings conference call on May 11, 2026, to discuss the company's recent financial performance and operational updates. The call featured key executives, including CEO Craig Collard, CFO Ira Duarte, COO Mark Hensley, and Chief Development Officer William Forbes. They addressed analysts from H.C. Wainwright & Co. and Needham & Company regarding the company's strategic direction and development pipeline. Melissa Jarel, Executive Director of Legal, opened the session with standard disclosures concerning forward-looking statements, cautioning investors that projections and expectations involve risks and uncertainties. The transcript provides insights into Heron Therapeutics' current business status, highlighting management's engagement with the investment community. As a biopharmaceutical company, Heron's updates are critical for stakeholders monitoring its progress in developing acute care therapies. The event serves as a formal platform for the company to communicate its quarterly results, answer investor questions, and outline future plans for the remainder of 2026, reflecting standard corporate transparency practices in the healthcare sector.
All Articles on Seeking Alpha